# A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

> **NCT04511013** · PHASE2 · RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 112 (estimated)

## Conditions studied

- Acral Lentiginous Melanoma
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Metastatic Cutaneous Melanoma
- Metastatic Malignant Neoplasm in the Brain
- Metastatic Melanoma
- Metastatic Mucosal Melanoma
- Pathologic Stage IV Cutaneous Melanoma AJCC v8

## Interventions

- **DRUG:** Binimetinib
- **DRUG:** Encorafenib
- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT04511013
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-06
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04511013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04511013, "A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04511013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*